日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Efficacy and Safety of ABBV-154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo-Controlled Trial

ABBV-154治疗活动性类风湿性关节炎的疗效和安全性：一项2b期随机、安慰剂对照试验

期刊:Arthritis & Rheumatology
影响因子:10.9
doi:10.1002/art.43266
Buttgereit, Frank; Singhal, Atul; Kivitz, Alan; Drescher, Edit; Taniguchi, Yoshinori; Pérez, Rosalía Martínez; Anderson, Jaclyn; D'Cunha, Ronilda; Zhao, Weihan; DeVogel, Nicholas; Parmentier, Julie; Christmann, Romy; Arikan, Dilek; Amital, Howard
关节炎
发表日期：2025
文献求助 收藏

Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 Study

静脉注射司库奇尤单抗治疗活动性银屑病关节炎的疗效和安全性：一项随机、安慰剂对照的3期研究结果

期刊:Arthritis & Rheumatology
影响因子:10.9
doi:10.1002/art.42997
Kivitz, Alan; Sedova, Liliana; Churchill, Melvin; Kotha, Roshan; Singhal, Atul; Torres, Alexander; Valenzuela, Guillermo; Whelan, Sarah; Dumortier, Thomas; Zhu, Xuan; Martin, Ruvie; Pricop, Luminita
关节炎
银屑病
发表日期：2025
文献求助 收藏

Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo-Controlled, Phase 3 Study

静脉注射司库奇尤单抗治疗活动性中轴型脊柱关节炎患者的疗效和安全性：一项随机、安慰剂对照的3期研究结果

期刊:Arthritis & Rheumatology
影响因子:10.9
doi:10.1002/art.42993
Deodhar, Atul; Supronik, Jerzy; Kivitz, Alan; Valenzuela, Guillermo; Kapur, Karen; Rohrer, Susanne; Dokoupilová, Eva; Richards, Hanno B; Pavelka, Karel
关节炎
发表日期：2025
文献求助 收藏

A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment

一项针对强直性脊柱炎患者（治疗16周后未达到疾病非活动期）的司库奇尤单抗剂量递增研究

期刊:Rheumatology
影响因子:4.4
doi:10.1093/rheumatology/keae432
Deodhar, Atul; Kivitz, Alan J; Magrey, Marina; Walsh, Jessica A; Mease, Philip J; Greenwald, Maria; Kianifard, Farid; Elam, Chelsea; Bommidi, Gopi M; Winseck, Adam; Gensler, Lianne S
强直性脊柱炎
免疫/内分泌
发表日期：2025
文献求助 收藏

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials

Risankizumab治疗活动性银屑病关节炎的疗效和安全性：KEEPsAKE 1和KEEPsAKE 2随机临床试验的196周结果

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-025-00793-3
Östör, Andrew; Van den Bosch, Filip; Papp, Kim; Keiserman, Mauro; Blanco, Ricardo; Crowley, Angela; White, Douglas; Biljan, Ana; Madihlaba, Tshepiso; Carter, Kyle; Liu, Fang; Soliman, Ahmed M; Ashley, Doug; Chen, Michael; Glotfelty, Lila; Kivitz, Alan
关节炎
银屑病
发表日期：2025
文献求助 收藏

Neuroimmune Modulation for Drug-Refractory Rheumatoid Arthritis: Long-Term Safety and Efficacy in Patients Enrolled in a Pilot Vagus Nerve Stimulation Study

神经免疫调节治疗药物难治性类风湿性关节炎：一项迷走神经刺激试点研究的长期安全性和有效性

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-025-00798-y
Gaylis, Norman B; Sikes, David; Kivitz, Alan; Horowitz, Diane Lewis; Evangelista, Melissa; Levine, Yaakov A; Chernoff, David
关节炎
免疫/内分泌
发表日期：2025
文献求助 收藏

Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial

Sonelokimab，一种用于治疗活动性银屑病关节炎的IL-17A/IL-17F抑制纳米抗体：一项随机、安慰剂对照的II期试验

期刊:Nature Medicine
影响因子:
doi:10.1038/s41591-025-03971-6
McInnes, Iain B; Coates, Laura C; Mease, Philip J; Ogdie, Alexis; Kavanaugh, Arthur; Eder, Lihi; Schett, Georg; Kivitz, Alan; McGonagle, Dennis; Brennan, Nuala; Godwood, Alex; Cullen, Eva; Reich, Kristian; Ritchlin, Christopher T; Merola, Joseph F
IL-17F
IL-17
IL-17A
银屑病
关节炎
发表日期：2025
文献求助 收藏

The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout

COMPARE 是一项头对头、随机对照试验，旨在比较 SEL-212（培加替酶联合雷帕霉素纳米颗粒，ImmTOR™）与培洛替酶治疗难治性痛风的疗效。

期刊:Rheumatology
影响因子:4.4
doi:10.1093/rheumatology/kead333
Baraf, Herbert S B; Khanna, Puja P; Kivitz, Alan J; Strand, Vibeke; Choi, Hyon K; Terkeltaub, Robert; Dalbeth, Nicola; DeHaan, Wesley; Azeem, Rehan; Traber, Peter G; Keenan, Robert T
痛风
mTOR
代谢
OMP
COMP
OMPA
发表日期：2024
文献求助 收藏

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial

Risankizumab治疗活动性银屑病关节炎的疗效和安全性：KEEPsAKE 2随机临床试验的100周结果

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-024-00657-2
Östör, Andrew; Van den Bosch, Filip; Papp, Kim; Asnal, Cecilia; Blanco, Ricardo; Aelion, Jacob; Carter, Kyle; Stakias, Vassilis; Lippe, Ralph; Drogaris, Leonidas; Soliman, Ahmed M; Chen, Michael M; Padilla, Byron; Kivitz, Alan
关节炎
银屑病
发表日期：2024
文献求助 收藏

Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies

塞库奇尤单抗治疗美国银屑病关节炎患者的疗效和安全性：3期FUTURE研究的亚组分析

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-024-00666-1
Kivitz, Alan J; Kremer, Joel M; Legerton, Clarence W 3rd; Pricop, Luminita; Singhal, Atul
关节炎
银屑病
发表日期：2024
文献求助 收藏